2013年8月7日讯--葛兰素史克（GSK）8月5日宣布，已收到FDA的批准，开始装运2013-2014季FLUARIX  QUADRIVALENT（流感疫苗），向美国疾控预防中心（CDC）配送中心和美国医疗保健提供者供货。该疫苗是首个上市销售的4价流感疫苗。

FLUARIX QUADRIVALENT于2012年12月14日获FDA批准，用于三岁以上儿童以及成年人的免疫接种，用于4个病毒株的预防，而不是平常的3个病毒株。

GSK 并不是唯一一家生产四家流感疫苗的厂家，今年3月初，FDA批准了世界首支四价流感疫苗—— 阿斯利康旗下子公司MedImmune的FluMist Quadrivalent vaccine。FluMist喷雾疫苗可用于2-49岁人群。该疫苗含针对两种甲型流感(H1N1,H3N2)和两种乙型流感(Victori,Yamagata)的抗原。

GSK预计，将为美国提供多达1000万剂四价流感疫苗。

英文原文：GlaxoSmithKline receives FDA approval to ship four-strain (quadrivalent) influenza vaccine to healthcare providers

GlaxoSmithKline receives FDA approval to ship four-strain (quadrivalent) influenza vaccine to healthcare providers

- First broadening of influenza-strain protection to occur in more than 30 years

PHILADELPHIA, Aug. 5, 2013 /PRNewswire/ -- GlaxoSmithKline [NYSE: GSK] announced today it has received U.S. Food and Drug Administration (FDA) approval to start shipping 2013-2014 FLUARIX? QUADRIVALENT (Influenza Virus Vaccine) to CDC distribution centers and U.S. healthcare providers. This is the first season that vaccines protecting against more than three strains of influenza (flu) will be commercially available.

Fluarix Quadrivalent was the first intramuscular quadrivalent influenza vaccine approved by the FDA [on December 14, 2012] for the immunization of children (three years and older) and adults to help prevent disease caused by seasonal influenza virus subtypes A and B contained in the vaccine. Before vaccine manufacturers can begin shipping influenza vaccines each season, the FDA first must certify that the supplies to be provided to healthcare providers meet the agency's quality and safety standards.

Scientists classify the influenza strains that cause seasonal influenza as A or B strains. Most current influenza vaccines provide trivalent (three-strain) influenza protection. Trivalent influenza vaccines protect against the two A virus strains most common in humans and the B strain expected to be predominant in a given year.

"Trivalent (three-strain) influenza vaccines offer important protection against influenza. But since the late 1980s, scientists noted that two B virus lineage strains circulate to varying degrees each year, and it's difficult to predict which one will cause the most illness in a particular influenza season," said Dr. Leonard Friedland, VP, Scientific Affairs and Public Policy, GSK Vaccines, North America. "Fluarix Quadrivalent addresses this by protecting against both B strains."

With today's FDA lot release, GSK's Fluarix Quadrivalent influenza vaccine soon will be supplied to U.S. healthcare providers who placed orders for the new vaccine after it was approved late last year. The CDC (U.S. Centers for Disease Control and Prevention) placed the largest order for Fluarix Quadrivalent - for more than four million doses - and will allocate those doses to U.S. state and local healthcare providers. The CDC annually purchases large quantities of influenza vaccines from multiple influenza manufacturers.

For this influenza season, GSK will supplement the supply of Fluarix Quadrivalent with its trivalent seasonal influenza vaccines. In the U.S., GSK estimates it will provide up to 10 million doses of quadrivalent influenza vaccines, and 22 to 24 million doses of influenza vaccines overall. GSK believes the healthcare community will steadily transition in coming years to quadrivalent influenza vaccines, and the company is in the process of increasing its capability to provide substantially more quadrivalent influenza vaccine doses for coming influenza seasons.